On January 10, 2023, Kirsten Flowers notified Kura Oncology, Inc. (the âCompanyâ) of her intention to resign from her position as the Companyâs Chief Commercial Officer, effective as of January 27, 2023 (the âSeparation Dateâ), in order to pursue other opportunities.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.17 USD | -1.21% | -4.51% | +47.22% |
15/05 | Transcript : Kura Oncology, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:40 AM | |
14/05 | Kura Oncology Enrolls 85 Patients in Ziftomenib Trial for Leukemia Drug | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+47.22% | 1.63B | |
+12.30% | 116B | |
+12.15% | 106B | |
-8.14% | 23.89B | |
-1.69% | 21.58B | |
-10.60% | 18.96B | |
-41.25% | 16.96B | |
-15.33% | 16.33B | |
+5.80% | 14.14B | |
+28.03% | 12.02B |
- Stock Market
- Equities
- KURA Stock
- News Kura Oncology, Inc.
- Kirsten Flowers Notifies Kura Oncology, Inc. of Resignation as Chief Commercial Officer